切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2018, Vol. 07 ›› Issue (04) : 284 -288. doi: 10.3877/cma.j.issn.2095-3232.2018.04.008

所属专题: 文献

临床研究

PTCD术前减黄在肝门部胆管癌半肝切除术中的应用
田峰1, 赵鑫1, 崔劲驰1, 李大江1, 陈志宇1, 李智华1, 何宇1,(), 王曙光1   
  1. 1. 400038 重庆,陆军军医大学第一附属医院全军肝胆外科研究所
  • 收稿日期:2018-05-11 出版日期:2018-08-10
  • 通信作者: 何宇
  • 基金资助:
    国家自然科学基金(81402406)

Application of preoperative percutaneous transhepatic cholangial drainage in partial hepatectomy of hepatic hilar cholangiocarcinoma

Feng Tian1, Xin Zhao1, Jingchi Cui1, Dajiang Li1, Zhiyu Chen1, Zhihua Li1, Yu He1,(), Shuguang Wang1   

  1. 1. Institute of Hepatobiliary Surgery, the First Hospital Affiliated to Army Medical University, Chongqing 400038, China
  • Received:2018-05-11 Published:2018-08-10
  • Corresponding author: Yu He
  • About author:
    Corresponding author: He Yu, Email:
引用本文:

田峰, 赵鑫, 崔劲驰, 李大江, 陈志宇, 李智华, 何宇, 王曙光. PTCD术前减黄在肝门部胆管癌半肝切除术中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2018, 07(04): 284-288.

Feng Tian, Xin Zhao, Jingchi Cui, Dajiang Li, Zhiyu Chen, Zhihua Li, Yu He, Shuguang Wang. Application of preoperative percutaneous transhepatic cholangial drainage in partial hepatectomy of hepatic hilar cholangiocarcinoma[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2018, 07(04): 284-288.

目的

探讨经皮经胆道引流(PTCD)术前减黄在肝门部胆管癌半肝切除中的应用价值。

方法

回顾性分析2008年1月至2013年1月陆军军医大学第一附属医院行半肝联合尾状叶切除的78例肝门部胆管癌患者临床资料。患者均签署知情同意书,符合医学伦理规定。根据是否行PTCD术前减黄分为PTCD组和非PTCD组。PTCD组57例,男34例,女23例;平均年龄(57±9)岁。非PTCD组21例,男12例,女9例;年龄(54±6)岁。两组患者TB、手术时间比较采用t检验,率的比较采用χ2检验,生存分析采用Kaplan-Meier法和Log-rank检验。

结果

PTCD组入院时TB为(295±131)μmol/L,明显高于非PTCD组的(137±37)μmol/L(t=3.768,P<0.05);而PTCD后TB降为(67±25) μmol/L,明显低于非PTCD组(t=-5.784,P<0.05)。PTCD相关并发症发生率16%(9/57),其中胆管炎发生率12%(7/57),出血和种植转移发生率均为2%(1/57)。PTCD组、非PTCD组手术时间分别为(490±153)、(488±93)min,差异无统计学意义(t=0.040,P>0.05)。PTCD组输血率、R0切除率、并发症发生率分别为79%、79%、42%,与非PTCD组的71%、86%、38%相比,差异无统计学意义(χ2=0.157,0.122,0.102;P>0.05)。两组术后均无发生肝衰竭和死亡。两组总体生存率和无瘤生存率比较差异无统计学意义(χ2=1.469,1.384;P>0.05)。

结论

PTCD应用于肝门部胆管癌术前减黄可明显降低胆红素水平,并不增加半肝切除手术风险,是安全、有效的,也不影响切除术后远期存活。

Objective

To evaluate the value of percutaneous transhepatic cholangial drainage (PTCD) before partial hepatectomy of hepatic hilar cholangiocarcinoma.

Methods

Clinical data of 78 patients with hepatic hilar cholangiocarcinoma who underwent partial hepatectomy combined with caudate lobectomy in the First Hospital Affiliated to Army Medical University between January 2008 and January 2013 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. According to whether preoperative PTCD was performed, patients were divided into the PTCD group (n=57) and non-PTCD group (n=21). In PTCD group, 34 patients were males and 23 were females, aged (57±9) years on average. In non-PTCD group, 12 cases were males and 9 werefemales, aged (54±6) years on average. Total bilirubin (TB) levels and operative time were compared between two groups using t test. The comparison of rates was performed using Chi-square test. Survival analysis was performed using Kaplan-Meier method and Log-rank test.

Results

Upon admission, the TB level in PTCD group was (295±131) μmol/L, which was significantly higher than (137±37) μmol/L in non-PTCD group (t=3.768, P<0.05). TB level decreased to (67±25) μmol/L after PTCD, significantly lower than that in non-PTCD group (t=-5.784, P<0.05). The incidence of PTCD-related complications was 16%(9/57), where cholangitis was 12%(7/57), bleeding 2%(1/57) and implantation metastasis 2%(1/57). The operation time in the PTCD and non-PTCD groups was (490±153) and (488±93) min respectively, where no significant difference was observed (t=0.040, P>0.05). In PTCD group, the blood transfusion rate, R0 resection rate, and incidence of complications were 79%, 79% and 42% respectively, compared with 71%, 86% and 38% in non-PTCD group, where no significant difference was observed (χ2=0.157, 0.122, 0.102; P>0.05). No liver failure or death occurred in both groups. There was no significant difference in the overall survival and disease-free survival between two groups (χ2=1.469, 1.384; P>0.05).

Conclusions

It is safe and effective to apply PTCD before partial hepatectomy of hepatic hilar cholangiocarcinoma, which can significantly reduce the TB level, while does not increase the risk of surgery and does not affect the postoperative long-term survival.

表1 PTCD组和非PTCD组一般临床资料比较
图1 PTCD组和非PTCD组患者Kaplan-Meier生存曲线
[1]
项灿宏,童翾.肝门部胆管癌外科治疗的进展与争议[J].中国普通外科杂志,2018,27(2):137-142.
[2]
张东,李文智,陶杰,等.389例肝门部胆管癌外科治疗回顾性分析——单中心11年经验总结[J/CD].中华肝脏外科手术学电子杂志,2017,6(6):464-468.
[3]
隋鑫磊,汤恢焕,肖广发,等.322例肝门部胆管癌的临床疗效及预后因素分析[J].中华消化外科杂志,2017,16(4):391-397.
[4]
Iacono C, Ruzzenente A, Campagnaro T, et al. Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection: highlights and drawbacks[J]. Ann Surg, 2013, 257(2):191-204.
[5]
Moole H, Bechtold M, Puli SR. Efficacy of preoperative biliary drainage in malignant obstructive jaundice: a meta-analysis and systematic review[J]. World J Surg Oncol, 2016, 14(1):182.
[6]
中华医学会外科学分会胆道外科学组,解放军全军肝胆外科专业委员会.肝门部胆管癌诊断和治疗指南(2013版)[J].中华外科杂志,2013,51(10):865-871.
[7]
Ito Y, Nakai Y, Isayama H, et al. Impact of preoperative biliary drainage on surgical outcomes in periampullary and hilar malignancy: a single-center experience[J]. Surg Laparosc Endosc Percutan Tech, 2016, 26(2):150-155.
[8]
Fang Y, Gurusamy KS, Wang Q, et al. Meta-analysis of randomized clinical trials on safety and efficacy of biliary drainage before surgery for obstructive jaundice[J]. Br J Surg, 2013, 100(12):1589-1596.
[9]
Igami T, Nishio H, Ebata T, et al. Surgical treatment of hilar cholangiocarcinoma in the "new era": the Nagoya University experience[J]. J Hepatobiliary Pancreat Sci, 2010, 17(4):449-454.
[10]
Jo JH, Chung MJ, Han DH, et al. Best options for preoperative biliary drainage in patients with Klatskin tumors[J]. Surg Endosc, 2017, 31(1):422-429.
[11]
Cai Y, Tang Q, Xiong X, et al. Preoperative biliary drainage versus direct surgery for perihilar cholangiocarcinoma: a retrospective study at a single center[J]. Biosci Trends, 2017, 11(3):319-325.
[12]
Hwang S, Song GW, Ha TY, et al. Reappraisal of percutaneous transhepatic biliary drainage tractrecurrence after resection of perihilar bile duct cancer[J]. World J Surg, 2012, 36(2):379-385.
[13]
Farges O, Regimbeau JM, Fuks D, et al. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma[J]. Br J Surg, 2013, 100(2):274-283.
[14]
Ruys AT, Heuts SG, Rauws EA, et al. Delay in surgical treatment of patients with hilar cholangiocarcinoma: does time impact outcomes?[J]. HPB, 2013, 16(5):469-474.
[15]
Hameed A, Pang T, Chiou J, et al. Percutaneous vs. endoscopic pre-operative biliary drainage in hilar cholangiocarcinoma-a systematic review and meta-analysis[J]. HPB, 2016, 18(5):400-410.
[16]
Zhang XF, Beal EW, Merath K, et al. Oncologic effects of preoperative biliary drainage in resectable hilar cholangiocarcinoma: percutaneous biliary drainage has no adverse effects on survival[J].J Surg Oncol, 2017, DOI:10.1002/jso.24945 [Epub ahead of print].
[17]
Tang Z, Yang Y, Meng W, et al. Best option for preoperative biliary drainage in Klatskin tumor: a systematic review and meta-analysis[J]. Medicine, 2017, 96(43):e8372.
[18]
Liu JG, Wu J, Wang J, et al. Endoscopic biliary drainage versus percutaneous transhepatic biliary drainage in patients with resectable hilar cholangiocarcinoma: a systematic review and meta-analysis[J]. J Laparoendosc Adv Surg Tech A, 2018, DOI:10.1089/lap.2017.0744[Epub ahead of print].
[19]
Al Mahjoub A, Menahem B, Fohlen A, et al. Preoperative biliary drainage in patients with resectable perihilar cholangiocarcinoma: is percutaneous transhepatic biliary drainage safer and more effective than endoscopic biliary drainage? a meta-analysis[J]. J Vasc Interv Radiol, 2017, 28(4):576-582.
[20]
Kawashima H, Itoh A, Ohno E, et al. Preoperative endoscopic nasobiliary drainage in 164 consecutive patients with suspected perihilar cholangiocarcinoma: a retrospective study of efficacy and risk factors related to complications[J]. Ann Surg, 2013, 257(1):121-127.
[21]
Nagino M. Perihilar cholangiocarcinoma: a surgeon's viewpoint on current topics[J]. J Gastroenterol, 2012, 47(11):1165-1176.
[1] 陆婷, 范晴敏, 王洁, 万晓静, 许春芳, 董凤林. 超声引导下经皮穿刺置管引流对重症急性胰腺炎的疗效及应用时机的选择[J/OL]. 中华医学超声杂志(电子版), 2024, 21(05): 511-516.
[2] 钟锴, 蒋铁民, 张瑞青, 吐尔干艾力·阿吉, 邵英梅, 郭强. 加速康复外科在肝囊型棘球蚴病肝切除术中的应用分析[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 425-429.
[3] 朴成林, 蓝炘, 司振铎, 李强, 冯健, 安峰铎, 冷建军. 胰十二指肠切除联合肝切除术疗效分析:附5例报告(附视频)[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 363-367.
[4] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[5] 冯旺, 马振中, 汤林花. CT扫描三维重建在肝内胆管细胞癌腹腔镜肝切除术中的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 104-107.
[6] 赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[7] 唐梅, 周丽, 牛岑月, 周小童, 王倩. ICG荧光导航的腹腔镜肝切除术临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 655-658.
[8] 胡森焱, 徐冬, 方健, 谢冬冬, 王财庆. ICG荧光显影Laennec膜入路腹腔镜解剖性肝切除的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 513-516.
[9] 林巧, 周丽. RFA联合LAH术治疗原发性肝癌并门静脉癌栓的临床效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 521-524.
[10] 杭轶, 杨小勇, 李文美, 薛磊. 可控性低中心静脉压技术在肝切除术中应用的最适中心静脉压[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 813-817.
[11] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[12] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[13] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[14] 吴雪云, 胡小军, 范应方. 肝切除术中剩余肝再生能力的评估与预测[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 894-897.
[15] 李新宇, 梁建锋. 3D打印导板辅助颅内血肿穿刺引流手术[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(06): 382-384.
阅读次数
全文


摘要